Cargando…

Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients

Detalles Bibliográficos
Autores principales:	Bitar, Carole, Maghfour, Jalal, Ho-Pham, Hoang, Stumpf, Brittany, Boh, Erin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357541/ https://www.ncbi.nlm.nih.gov/pubmed/30740504 http://dx.doi.org/10.1016/j.jdcr.2018.11.019

Ejemplares similares

Apremilast as a treatment for morphea: A case series
por: Koschitzky, Merav, et al.
Publicado: (2021)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series
por: Levine, Todd
Publicado: (2012)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Erythromelalgia associated with dermatomyositis: A case series
por: Grinnell, Madison, et al.
Publicado: (2021)

Dermatomyositis recalcitrant to treatment associated with occult malignancy
por: Kane, Jennifer, et al.
Publicado: (2019)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Distinctive cutaneous features of dermatomyositis in Black adults: A case series
por: Ezeofor, Adaeze J., et al.
Publicado: (2023)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

Spontaneous Pneumomediastinum and Subcutaneous Emphysema in Dermatomyositis: A Case Series and Literature Review
por: Subki, Ahmed Hussein, et al.
Publicado: (2023)

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
por: Srivastava, Divyanshu, et al.
Publicado: (2023)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
por: Vossen, A.R.J.V., et al.
Publicado: (2018)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series
por: Hosono, Shusaku, et al.
Publicado: (2020)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer’s disease
por: Maynard, Steven Douglas, et al.
Publicado: (2013)

Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
por: Imafuku, Shinichi, et al.
Publicado: (2020)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Repigmentation of Tenacious Vitiligo on Apremilast
por: Huff, Sara B., et al.
Publicado: (2017)

Apremilast in Refractory Alopecia Areata
por: Estébanez, Andrea, et al.
Publicado: (2019)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report
por: Zarbafian, Misha, et al.
Publicado: (2019)

Two Cases of Treatment of Moderate to Severe Acne with an Acupuncture-Debridement Microsurgical Technique and Review of the Literature
por: Jia, Renchuan, et al.
Publicado: (2023)

Treatment of a perforating dermatosis with apremilast
por: McMichael, Josette, et al.
Publicado: (2021)

Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study
por: Kato, Noriko, et al.
Publicado: (2021)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
por: Zargaran, Marzieh, et al.
Publicado: (2021)

Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: Scoping Review
por: Maghfour, Jalal, et al.
Publicado: (2021)

COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
por: Babadjouni, Arish, et al.
Publicado: (2022)

Worsening of Lymphopenia during Apremilast Treatment
por: Kolios, Antonios G.A., et al.
Publicado: (2016)

Apremilast for treatment of recalcitrant aphthous stomatitis
por: Schibler, Fabian, et al.
Publicado: (2017)

Apremilast as an adjuvant therapy for calcinosis cutis
por: Qiblawi, Sultan H., et al.
Publicado: (2019)

Apremilast in the Management of Disseminated Granuloma Annulare
por: Joshi, Tejas P, et al.
Publicado: (2021)

Beneficial Impact of Apremilast on Palmoplantar Keratodermas
por: NAKAJIMA, Kimiko, et al.
Publicado: (2021)

Treatment of pyoderma gangrenosum with apremilast monotherapy
por: Bordeaux, Zachary A., et al.
Publicado: (2022)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_thnn6vn4u4rs525oq9puevqb5r